SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor [Yahoo! Finance]
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
COGT Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]